S7326

SB 657510

≥98% (HPLC)

• Sinónimos: 2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxy-benzenesulfonamide, SB-657510
• Fórmula empírica (notación de Hill): C₁₉H₂₂BrClN₂O₅S
• Número CAS: 474960-44-6
• Peso molecular: 505.81
• UNSPSC Code: 12352200
• PubChem Substance ID: 329824581
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: ≥30 mg/mL
• originator: GlaxoSmithKline
• storage temp.: room temp
• SMILES string: COc1cc(Br)c(cc1OC)S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2
• InChI: 1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3/t13-/m1/s1
• InChI key: KQCZCINJGIRLCD-CYBMUJFWSA-N

Descripción

Application

SB 657510 may be used to study the urotensin II receptor-mediated signaling.

Biochem/physiol Actions

SB 657510 is a potent and selective urotensin-II (UT) receptor antagonist.

SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.¹

SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H315,H319,H335
• pcodes: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable